Agios Pharmaceuticals Ownership | Who Owns Agios Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Agios Pharmaceuticals Ownership Summary


Agios Pharmaceuticals is owned by 59.29% institutional investors, 1.73% insiders, and 38.98% retail investors. Farallon capital management is the largest institutional shareholder, holding 9.98% of AGIO shares. BB Biotech AG Ord is the top mutual fund, with 6.16% of its assets in Agios Pharmaceuticals shares.

AGIO Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAgios Pharmaceuticals59.29%1.73%38.98%
SectorHealthcare Stocks 232.52%10.72%-143.24%
IndustryBiotech Stocks 384.56%10.59%-295.14%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Farallon capital management5.78M9.98%$232.05M
Vanguard group5.59M9.62%$152.28M
Blackrock funding, inc. /de5.24M9.01%$142.51M
Blackrock4.86M8.55%$209.52M
Bellevue group3.71M6.41%$149.11M
Erste asset management gmbh2.80M4.82%$76.34M
Paradigm biocapital advisors lp2.67M4.61%$107.32M
Wellington management group llp2.47M4.27%$99.20M
Commodore capital lp2.34M4.04%$93.86M
State street2.26M3.91%$90.83M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Caligan partners lp1.13M5.95%$45.41M
Commodore capital lp2.34M4.58%$93.86M
Cutter capital management, lp301.62K4.06%$9.91M
Bellevue group3.71M3.10%$149.11M
Paradigm biocapital advisors lp2.67M3.05%$107.32M
Tcg crossover management1.43M2.82%$57.40M
Rock springs capital management lp958.54K2.25%$38.48M
Palo alto investors lp265.50K1.97%$10.66M
Highvista strategies195.30K1.92%$7.84M
Frazier life sciences management1.28M1.54%$51.37M

Top Buyers

HolderShares% AssetsChange
Wellington management group llp2.47M0.02%2.05M
Paradigm biocapital advisors lp2.67M3.05%1.53M
Tcg crossover management1.43M2.82%733.04K
Jane street group1.12M0.00%725.93K
Capital investors703.87K0.00%703.87K

Top Sellers

HolderShares% AssetsChange
Macquarie group---1.96M
Jefferies financial group---1.50M
Bvf inc/il---1.07M
Polar capital---1.00M
T. rowe price investment management---928.60K

New Positions

HolderShares% AssetsChangeValue
Capital investors703.87K0.00%703.87K$19.16M
Axa investment managers177.68K0.02%177.68K$7.13M
Group one trading166.61K0.01%166.61K$4.54M
Hrt financial lp146.47K0.01%146.47K$3.99M
Norges bank145.09K0.00%145.09K$4.77M

Sold Out

HolderChange
National bank of canada /fi/-1.00
Dinuzzo private wealth-1.00
Global financial private client-3.00
Riggs asset managment-3.00
Hfm investment advisors-3.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025165-31.82%34,473,117-45.71%590.49%89-24.58%49-28.99%
Sep 30, 20252299.05%60,859,3063.40%1051.02%1114.72%67-6.94%
Jun 30, 2025217-3.56%61,654,5153.33%1060.99%108-5.26%765.56%
Mar 31, 2025223-4.29%59,949,9120.23%1040.95%113-12.40%712.90%
Dec 31, 20242314.05%58,738,5911.40%1031.00%12622.33%702.94%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
BB Biotech AG Ord3.52M6.16%-220.76K
Vanguard US Total Market Shares ETF1.79M3.12%2.35K
Vanguard Total Stock Mkt Idx Inv1.81M3.11%-38.53K
Macquarie Small Cap Core I1.43M2.46%-107.41K
Delaware Small Cap Core I1.38M2.42%-8.55K
Vanguard Small Cap Index1.41M2.42%-9.02K
iShares Russell 2000 ETF1.36M2.34%-
Polar Capital Biotech S Inc1.00M1.73%-
T. Rowe Price Health Sciences979.66K1.69%-10.99K
DWS Vermögensbildungsfonds I LD805.52K1.39%3.00

Recent Insider Transactions


DateNameRoleActivityValue
Jan 05, 2026Milanova Tsveta Chief Commercial OfficerSell$77.60K
Dec 30, 2025Burns James William Chief Legal OfficerSell$79.43K
Dec 30, 2025Goff Brian Chief Executive OfficerSell$337.89K
Dec 30, 2025Goff Brian Chief Executive OfficerSell$168.77K
Dec 30, 2025Gheuens Sarah Chief Medical OfficerSell$79.43K

Insider Transactions Trends


DateBuySell
2026 Q1-1
2025 Q4-11
2025 Q3-9
2025 Q2-7
2025 Q1-16

AGIO Ownership FAQ


Who Owns Agios Pharmaceuticals?

Agios Pharmaceuticals shareholders are primarily institutional investors at 59.29%, followed by 1.73% insiders and 38.98% retail investors. The average institutional ownership in Agios Pharmaceuticals's industry, Biotech Stocks , is 384.56%, which Agios Pharmaceuticals falls below.

Who owns the most shares of Agios Pharmaceuticals?

Agios Pharmaceuticals’s largest shareholders are Farallon capital management (5.78M shares, 9.98%), Vanguard group (5.59M shares, 9.62%), and Blackrock funding, inc. /de (5.24M shares, 9.01%). Together, they hold 28.61% of Agios Pharmaceuticals’s total shares outstanding.

Does Blackrock own Agios Pharmaceuticals?

Yes, BlackRock owns 8.55% of Agios Pharmaceuticals, totaling 4.86M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 209.52M$. In the last quarter, BlackRock increased its holdings by 200.91K shares, a 4.31% change.

Who is Agios Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Caligan partners lp is Agios Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 5.95% of its assets in 1.13M Agios Pharmaceuticals shares, valued at 45.41M$.

Who is the top mutual fund holder of Agios Pharmaceuticals shares?

BB Biotech AG Ord is the top mutual fund holder of Agios Pharmaceuticals shares, with 6.16% of its total shares outstanding invested in 3.52M Agios Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools